These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 23387374)

  • 1. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
    Ports WC; Khan S; Lan S; Lamba M; Bolduc C; Bissonnette R; Papp K
    Br J Dermatol; 2013 Jul; 169(1):137-45. PubMed ID: 23387374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
    Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
    BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.
    Bissonnette R; Papp KA; Poulin Y; Gooderham M; Raman M; Mallbris L; Wang C; Purohit V; Mamolo C; Papacharalambous J; Ports WC
    Br J Dermatol; 2016 Nov; 175(5):902-911. PubMed ID: 27423107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
    Papp KA; Menter MA; Abe M; Elewski B; Feldman SR; Gottlieb AB; Langley R; Luger T; Thaci D; Buonanno M; Gupta P; Proulx J; Lan S; Wolk R;
    Br J Dermatol; 2015 Oct; 173(4):949-61. PubMed ID: 26149717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
    Bissonnette R; Iversen L; Sofen H; Griffiths CE; Foley P; Romiti R; Bachinsky M; Rottinghaus ST; Tan H; Proulx J; Valdez H; Gupta P; Mallbris L; Wolk R
    Br J Dermatol; 2015; 172(5):1395-406. PubMed ID: 25418186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
    Papp KA; Menter A; Strober B; Langley RG; Buonanno M; Wolk R; Gupta P; Krishnaswami S; Tan H; Harness JA
    Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
    Strober BE; Gottlieb AB; van de Kerkhof PCM; Puig L; Bachelez H; Chouela E; Imafuku S; Thaçi D; Tan H; Valdez H; Gupta P; Kaur M; Frajzyngier V; Wolk R
    Br J Dermatol; 2019 Jan; 180(1):67-75. PubMed ID: 30188571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning.
    Purohit VS; Ports WC; Wang C; Riley S
    J Clin Pharmacol; 2019 Jun; 59(6):811-820. PubMed ID: 30556911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
    Asahina A; Etoh T; Igarashi A; Imafuku S; Saeki H; Shibasaki Y; Tomochika Y; Toyoizumi S; Nagaoka M; Ohtsuki M;
    J Dermatol; 2016 Aug; 43(8):869-80. PubMed ID: 26875540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
    Papp KA; Krueger JG; Feldman SR; Langley RG; Thaci D; Torii H; Tyring S; Wolk R; Gardner A; Mebus C; Tan H; Luo Y; Gupta P; Mallbris L; Tatulych S
    J Am Acad Dermatol; 2016 May; 74(5):841-50. PubMed ID: 26899199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.
    Valenzuela F; Korman NJ; Bissonnette R; Bakos N; Tsai TF; Harper MK; Ports WC; Tan H; Tallman A; Valdez H; Gardner AC
    Br J Dermatol; 2018 Oct; 179(4):853-862. PubMed ID: 29782642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C; Harness J; Tan H; Menter A
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
    Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
    J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
    Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
    Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
    Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T
    J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis.
    Bagherani N; Smoller BR
    Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28133877
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
    Krishnaswami S; Boy M; Chow V; Chan G
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.
    Strober B; Buonanno M; Clark JD; Kawabata T; Tan H; Wolk R; Valdez H; Langley RG; Harness J; Menter A; Papp K
    Br J Dermatol; 2013 Nov; 169(5):992-9. PubMed ID: 23855761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
    Kuo CM; Tung TH; Wang SH; Chi CC
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):355-362. PubMed ID: 29136293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.